Monday, 27 May 2019

Sandoz launches trial with Amgen biosimilar

26 June 2013 | News | By BioSpectrum Bureau

Novartis has launched a late-stage trial with its biosimilar version of Amgen's Enbrel

Novartis has launched a late-stage trial with its biosimilar version of Amgen's Enbrel

Singapore: The generics unit of Novartis, Sandoz, has launched a late-stage trial with its biosimilar version of Amgen's Enbrel. With this, Novartis has consolidated its leading position in developing cheaper copies of complex biotech drugs.

Sandoz currently has seven phase III clinical trials across five biosimilar molecules, including the start of the major study of its version of Enbrel or etanercept.

The company has said that the new trial aims to confirm the biosimilarity of its product versus Enbrel in patients with moderate to severe chronic plaque-type psoriasis. Results will be used to support US and European regulatory filings.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Will stem cell therapy market witness highest growth in Asia by 2020?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls